Literature DB >> 30016594

Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).

Longfa Kou1, Rui Sun1, Vadivel Ganapathy1,2, Qing Yao3, Ruijie Chen1.   

Abstract

INTRODUCTION: Transporters in the plasma membrane have been exploited successfully for the delivery of drugs in the form of prodrugs and nanoparticles. Organic cation/carnitine transporter 2 (OCTN2, SLC22A5) has emerged as a viable target for drug delivery. OCTN2 is a Na+-dependent high-affinity transporter for L-carnitine and a Na+-independent transporter for organic cations. OCTN2 is expressed in the blood-brain barrier, heart, liver, kidney, intestinal tract and placenta and plays an essential role in L-carnitine homeostasis in the body. Areas covered: In recent years, several studies have been reported in the literature describing the utility of OCTN2 to enhance the delivery of drugs, prodrugs and nanoparticles. Here we summarize the salient features of OCTN2 in terms of its role in the cellular uptake of its physiological substrate L-carnitine in physiological and pathological context; the structural requirements for recognition and the recent advances in OCTN2-targeted drug delivery systems, including prodrugs and nanoparticles, are discussed. Expert opinion: This transporter has great potential to be utilized as a target for drug delivery to improve oral absorption of drugs in the intestinal tract. It also has potential to facilitate the transfer of drugs across the biological barriers such as the blood-brain barrier, blood-retinal barrier, and maternal-fetal barrier.

Entities:  

Keywords:  L-carnitine; OCTN2; biological barriers; drug delivery; nanoparticles; oral absorption; prodrugs

Mesh:

Substances:

Year:  2018        PMID: 30016594     DOI: 10.1080/14728222.2018.1502273

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  9 in total

Review 1.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

Review 2.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 3.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

Review 4.  Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?

Authors:  Elena Puris; Gert Fricker; Mikko Gynther
Journal:  Pharm Res       Date:  2022-03-31       Impact factor: 4.580

5.  Functional analysis of OCTN2 and ATB0,+ in normal human airway epithelial cells.

Authors:  Bianca Maria Rotoli; Rossana Visigalli; Amelia Barilli; Francesca Ferrari; Massimiliano G Bianchi; Maria Di Lascia; Benedetta Riccardi; Paola Puccini; Valeria Dall'Asta
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

6.  OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery in vitro, in situ, and in vivo.

Authors:  Longfa Kou; Rui Sun; Shuyi Xiao; Xiao Cui; Jin Sun; Vadivel Ganapathy; Qing Yao; Ruijie Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 7.  Cysteine Donor-Based Brain-Targeting Prodrug: Opportunities and Challenges.

Authors:  Gaoyang Ni; Zhenbiao Hu; Ziteng Wang; Min Zhang; Xingyu Liu; Guihong Yang; Zhaowei Yan; Yang Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-02-24       Impact factor: 6.543

Review 8.  Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy.

Authors:  Longfa Kou; Shuyi Xiao; Rui Sun; Shihui Bao; Qing Yao; Ruijie Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 9.  SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.

Authors:  Barbara Juraszek; Katarzyna A Nałęcz
Journal:  Molecules       Date:  2019-12-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.